Mitokinin to present at the Keystone Symposium on Neurodegeneration
June 15, 2019
Mitokinin, a late-preclinical stage biotechnology company developing PINK1-targeted therapies for Parkinson’s disease, shared a research update at this year’s Keystone Symposum on neurodegenerative diseases. In its presentation, the Company highlighted the impact of its lead candidate, MTK-458, on -synuclein pathology in cellular models of Parkinson’s disease.
“What we are presenting at the show represents the culmination of several years of dedicated research,” said Nicholas Hertz, PhD, Mitokinin’s Chief Science Officer. “We are the first group to show that pharmacological amplification of PINK1 activity could reduce-synuclein levels in Parkinson’s-patient-derived iPSC neurons and mouse primary neurons treated with PFFs. We also took the next step by linking that clearance to mitophagy specifically, which we believe to be a groundbreaking result for the PINK1/Parkin field, and further validation of our therapeutic approach in sporadic Parkinson’s disease.”
Copies of Mitokinin’s presentation can be requested via the Contact Us form on Mitokinin’s website.
Mitokinin is late-preclinical stage biotechnology company developing PINK1-targeted therapeutics for Parkinson’s disease. By selectively amplifying active-form PINK1 activity, Mitokinin believes it can address the cellular pathologies underlying Parkinson’s disease and ultimately slow or halt the progression of the disease. Learn more at www.mitokinin.com.